PDF herunterladen
neuroreha 2017; 09(03): 119-124
DOI: 10.1055/s-0043-116803
Schwerpunkt Neurochirurgie
Georg Thieme Verlag KG Stuttgart · New York

Tiefe Hirnstimulation bei Morbus Parkinson

Laura Paschen
,
Karsten Witt
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
14. September 2017 (online)

    Lizenzen und Reprints

Zusammenfassung

Etwa 12.500 Menschen/Jahr erhalten in Deutschland die Diagnose Morbus Parkinson und sehen sich mit Einschränkung, Stigma und Invalidität konfrontiert. Obwohl sich die Lebenserwartung der Erkrankten deutlich gebessert hat, ist die Diagnose daher weiterhin mit Angst verbunden. Medikamentöse Therapie und aktivierende Behandlungsmethoden haben einen wichtigen Stellenwert, dennoch entwickeln sich häufig motorische Wirkfluktuationen, die sich medikamentös nicht auffangen lassen. Seit nunmehr 30 Jahren ist jedoch die Tiefe Hirnstimulation verfügbar. Sie steht seither für die Faszination, die Funktion des Gehirns zu modulieren, und für die damit oftmals verbundene große Chance auf ein besseres Leben mit der unheilbaren Erkrankung.

 

  • Literatur

  • 1 Barone P, Antonini A, Colosimo C. et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 2009; 24: 1641-1649
    CrossrefPubMedGoogle Scholar
  • 2 Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: Diagnosis and management. Lancet Neurol 2006; 5: 235-245
    CrossrefPubMedGoogle Scholar
  • 3 Deuschl G, Herzog J. et al. Deep brain stimulation: Postoperative issues. Mov Disord 2006; 21
    Google Scholar
  • 4 Deuschl G, Schade-Brittinger C, Krack P. et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 2006; 355: 896-908
    CrossrefPubMedGoogle Scholar
  • 5 Deuschl G, Paschen S, Witt K. Clinical outcome of deep brain stimulation for Parkinson’s disease. Handb Clin Neurol 2013; 116C: 107-128
    Google Scholar
  • 6 Deuschl G, Schupbach M, Knudsen K. et al. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson’s disease: Concept and standards of the EARLYSTIM-study. Parkinsonism Relat Disord 2013; 19: 56-61
    CrossrefPubMedGoogle Scholar
  • 7 Deutsche Gesellschaft für Neurologie, DGN. S3-Leitlinie: Idiopathisches Parkinson-Syndrom – Langversion. Im Internet: https://www.dgn.org/images/red_leitlinien/LL_2016/PDFs_Download/030010_LL_langfassung_ips_2016.pdf Stand: 07.07.2017
    Google Scholar
  • 8 Doshi PK. Long-term surgical and hardware-related complications of deep brain stimulation. Stereotact Funct Neurosurg 2011; 89: 89-95
    CrossrefPubMedGoogle Scholar
  • 9 Falowski S, Ooi YC, Smith A. et al. An evaluation of hardware and surgical complications with deep brain stimulation based on diagnosis and lead location. Stereotact Funct Neurosurg 2012; 90: 173-180
    CrossrefPubMedGoogle Scholar
  • 10 Follett KA, Weaver FM, Stern M. et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N Engl J Med 2010; 362: 2077-2091
    CrossrefPubMedGoogle Scholar
  • 11 Greenberg BD. et al. Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: Worldwide experience. Mol Psychiatry 2010; 15 (01) 64-79 DOI: 10.1038/mp.2008.55
    CrossrefPubMedGoogle Scholar
  • 12 Hjort N, Ostergaard K, Dupont E. Improvement of sleep quality in patients with advanced Parkinson’s disease treated with deep brain stimulation of the subthalamic nucleus. Mov Disord 2004; 19: 196-199
    CrossrefPubMedGoogle Scholar
  • 13 Kim HJ, Paek SH, Kim JY. et al. Chronic subthalamic deep brain stimulation improves pain in Parkinson disease. J Neurol 2008; 255: 1889-1894
    CrossrefPubMedGoogle Scholar
  • 14 Kimmelman J, Duckworth K, Ramsay T. et al. Risk of surgical delivery to deep nuclei: A meta-analysis. Mov Disord 2011; 26: 1415-1421
    CrossrefPubMedGoogle Scholar
  • 15 Kleiner-Fisman G, Herzog J, Fisman DN. et al. Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes. Mov Disord 2006; 21 (Suppl. 14) S290-304
    CrossrefPubMedGoogle Scholar
  • 16 Lozano AM. et al. A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression. J Neurosurg 2012; 116 (02) 315-322 DOI: 10.3171/2011.10.JNS102122
    CrossrefPubMedGoogle Scholar
  • 17 Lozano AM, Fosdick L. et al. A phase II study of fornix deep brain stimulation in mild Alzheimer’s disease. J Alzheimers Dis 2016; 54 (02) 777-787 DOI: 10.3233/JAD-160017
    CrossrefPubMedGoogle Scholar
  • 18 Miocinovic S, Somayajula S, Chitnis S. et al. History, applications, and mechanisms of deep brain stimulation. JAMA Neurol 2013; 70: 163-171
    CrossrefPubMedGoogle Scholar
  • 19 Montgomery jr EB, Gale JT. Mechanisms of action of deep brain stimulation (DBS). Neurosci Biobehav Rev 2008; 32: 388-407
    CrossrefPubMedGoogle Scholar
  • 20 Odekerken VJ, Van Laar T, Staal MJ. et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson’s disease (NSTAPS study): A randomised controlled trial. Lancet Neurol 2013; 12: 37-44
    CrossrefPubMedGoogle Scholar
  • 21 Okun MS, Gallo BV, Mandybur G. et al. Subthalamic deep brain stimulation with a constant-current device in Parkinson’s disease: An open-label randomised controlled trial. Lancet Neurol 2012; 11: 140-149
    CrossrefPubMedGoogle Scholar
  • 22 Riva-Posse P, Holtzheimer PE, Garlow SJ. et al. Practical considerations in the development and refinement of subcallosal cingulate white matter deep brain stimulation for the treatment resistant depression. World Neurosurg 2012; pii S1878–8750(12)01436–2
    Google Scholar
  • 23 Schulte E, Schumacher U, Schünke M. et al. Prometheus – LernAtlas der Anatomie: Kopf und Neuroanatomie. Stuttgart: Thieme; 2006
    Google Scholar
  • 24 Thobois S, Ardouin C, Lhommee E. et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: Predictors and underlying mesolimbic denervation. Brain 2010; 133 (Pt 4) 1111-1127
    CrossrefPubMedGoogle Scholar
  • 25 Thobois S, Lhommee E, Klinger H. et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013; 136 (Pt 5) 1568-1577
    CrossrefPubMedGoogle Scholar
  • 26 Vergani F, Landi A, Pirillo D. et al. Surgical, medical, and hardware adverse events in a series of 141 patients undergoing subthalamic deep brain stimulation for Parkinson disease. World Neurosurg 2010; 73: 338-344
    CrossrefPubMedGoogle Scholar
  • 27 Voges J, Hilker R, Botzel K. et al. Thirty days complication rate following surgery performed for deep-brain-stimulation. Mov Disord 2007; 22: 1486-1489
    CrossrefPubMedGoogle Scholar
  • 28 Volkmann J, Daniels C, Witt K. Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nat Rev Neurol 2010; 6 (09) 487-498
    CrossrefPubMedGoogle Scholar
  • 29 Winge K, Nielsen KK, Stimpel H. et al. Lower urinary tract symptoms and bladder control in advanced Parkinson’s disease: Effects of deep brain stimulation in the subthalamic nucleus. Mov Disord 2007; 22: 220-225
    CrossrefPubMedGoogle Scholar
  • 30 Witt K, Daniels C, Reiff J. et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: A randomised, multicentre study. Lancet Neurol 2008; 7: 605-614
    CrossrefPubMedGoogle Scholar